153 related articles for article (PubMed ID: 9288701)
1. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch.
Bacchi-Modena A; Bolis P; Campagnoli C; De Cicco F; Meschia M; Pansini F; Pisati R; Hüls G
Maturitas; 1997 Jul; 27(3):285-92. PubMed ID: 9288701
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of a new estradiol delivering matrix patch (Estraderm MX) in postmenopausal women.
de Vrijer B; Snijders MP; Troostwijk AL; Thé S; Iding RJ; Friese S; Smit DA; Schierbeek JM; Brandts H; van Kempen PJ; van Buuren I; Monza G
Maturitas; 2000 Jan; 34(1):47-55. PubMed ID: 10687882
[TBL] [Abstract][Full Text] [Related]
3. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women.
Rohr UD; Nauert C; Stehle B
Maturitas; 1999 Sep; 33(1):45-58. PubMed ID: 10585173
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of Menorest 50 compared with Estraderm TTS 50 in the treatment of postmenopausal symptoms. A randomized, multicenter, parallel group study.
Pornel B; Genazzani AR; Costes D; Dain MP; Lelann L; Vandepol C
Maturitas; 1995 Nov; 22(3):207-18. PubMed ID: 8746878
[TBL] [Abstract][Full Text] [Related]
5. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with a seven-day estradiol transdermal system for estrogen replacement therapy.
Gordon SF
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 2):998-1004. PubMed ID: 7573298
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms.
Speroff L; Whitcomb RW; Kempfert NJ; Boyd RA; Paulissen JB; Rowan JP
Obstet Gynecol; 1996 Oct; 88(4 Pt 1):587-92. PubMed ID: 8841224
[TBL] [Abstract][Full Text] [Related]
8. Serum concentrations of 17beta-estradiol and estrone after multiple-dose administration of percutaneous estradiol gel in symptomatic menopausal women.
Brennan JJ; Lu Z; Whitman M; Stafiniak P; van der Hoop RG
Ther Drug Monit; 2001 Apr; 23(2):134-8. PubMed ID: 11294513
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints.
von Holst T; Salbach B
Maturitas; 2000 Feb; 34(2):143-53. PubMed ID: 10714909
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). II. Local skin tolerability.
Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J; Thebault J
Maturitas; 1996 Nov; 25(3):175-85. PubMed ID: 8981334
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of estradiol and of estrone during application of a new 7-day estradiol transdermal patch with active matrix.
Setnikar I; Rovati LC; Vens-Cappell B; Hilgenstock C
Arzneimittelforschung; 1998 Mar; 48(3):275-85. PubMed ID: 9553686
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy.
Rozenbaum H; Birkhäuser M; De Nooyer C; Lambotte R; Pornel B; Schneider H; Studd J
Maturitas; 1996 Nov; 25(3):161-73. PubMed ID: 8981333
[TBL] [Abstract][Full Text] [Related]
13. Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study. Italian Menopause Research Group.
Rovati LC; Setnikar I; Genazzani AR
Gynecol Endocrinol; 2000 Aug; 14(4):282-91. PubMed ID: 11075300
[TBL] [Abstract][Full Text] [Related]
14. Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. A randomized, double-blind placebo-controlled study.
De Aloysio D; Rovati LC; Giacovelli G; Setnikar I; Bottiglioni F
Arzneimittelforschung; 2000 Mar; 50(3):293-300. PubMed ID: 10758784
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of intranasal and transdermal estradiol.
Lopes P; Merkus HM; Nauman J; Bruschi F; Foidart JM; Calaf J
Obstet Gynecol; 2000 Dec; 96(6):906-12. PubMed ID: 11084176
[TBL] [Abstract][Full Text] [Related]
16. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerance of Menorest compared to Premarin in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study.
Studd JW; McCarthy K; Zamblera D; Burger HG; Silberberg S; Wren B; Dain MP; Le Lann L; Vandepol C
Maturitas; 1995 Sep; 22(2):105-14. PubMed ID: 8538478
[TBL] [Abstract][Full Text] [Related]
18. Use of a new transdermal delivery system for estrogen replacement therapy in postmenopausal women.
Figueroa-Casas PR; Alfonsin A; Arrighi A; Bluvstein G; Del Castillo R; Goldsman T; Inglesi J; Itala J; Novelli J; Monti C
Maturitas; 1994 Dec; 20(2-3):139-44. PubMed ID: 7715465
[TBL] [Abstract][Full Text] [Related]
19. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study.
Asthana S; Craft S; Baker LD; Raskind MA; Birnbaum RS; Lofgreen CP; Veith RC; Plymate SR
Psychoneuroendocrinology; 1999 Aug; 24(6):657-77. PubMed ID: 10399774
[TBL] [Abstract][Full Text] [Related]
20. Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women.
Slater CC; Hodis HN; Mack WJ; Shoupe D; Paulson RJ; Stanczyk FZ
Menopause; 2001; 8(3):200-3. PubMed ID: 11355042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
